Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx in Antibody Deal with BD Biosciences

NEW YORK, July 30 – Protein chip maker Zyomyx of Hayward, Calif., said Monday it had entered into an agreement for access to BD Biosciences' antibody collection.

Under the terms of the deal, Zyomyx will have access to BD Biosciences' antibodies for use in protein biochip development. BD Biosciences will also develop other antibodies exclusively for Zyomyx. 

Zyomyx did not disclose financial terms of the agreement.

"This collaboration greatly expands Zyomyx' antibody resources and enhances our capability to develop superior protein biochips," Lawrence Cohen, CEO of Zyomyx, said in a statement.

Zyomyx is currently developing chips designed to detect up to 10,000 different proteins. The company has previously signed deals with Cambridge Antibody Technology and Dyax for access to their antibody resources and technologies.

Zyomyx previously said it planned to launch beta tests of its protein chips in the first half of 2001.

BD Biosciences of Franklin Lakes, NJ, is a division of Becton, Dickinson.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.